key: cord-0864031-oewq0xgq
authors: Mueller, Thomas
title: Time course of antibody concentrations against the spike protein of SARS‐CoV‐2 among healthy hospital workers up to 200 days after their first COVID‐19 vaccination
date: 2021-12-14
journal: J Clin Lab Anal
DOI: 10.1002/jcla.24175
sha: 24ee8853fa1817af218cfe52977355bd60d95609
doc_id: 864031
cord_uid: oewq0xgq

nan

more antibodies and this in turn is closely related to better protection against the infection. 1 Therefore, it may be interesting to know the antibody concentration after vaccination over time.

We recently presented antibody levels after messenger RNA (mRNA) vaccination in healthy individuals over time up to five weeks after the initial injection. 2 The aim of the present work is now to describe the vaccination titers as measured with the Roche Elecsys Anti-SARS-CoV-2 S assay over time up to 200 days after the first injection. For this purpose, we followed up the same subjects as described in our original publication. 2 In brief, the original cohort consisted of 34 employees of the Department of Clinical Pathology of Bolzano who received their first COVID-19 vaccination between December 29, 2020 and January 14, 2021 and their second injection three weeks after the first vaccination. 2 All vaccinations were administered using the BioNTech/ Pfizer's BNT162b2 COVID-19 vaccine in two doses at the dose prescribed by the manufacturer. 2 The 34 participants (10 male and 24 female) had a median age of 50 years (range, 24-62 years). 

We would like to thank the staff of the Department of Clinical Pathology, Hospital of Bolzano, for their support in this project. We thank Maurizio Tait for the excellent technical assistance with the Elecsys Anti-SARS-CoV-2 assay and the Elecsys Anti-SARS-CoV-2 S assay.

None declared.

Thomas Mueller: Conceptualization, data collection, data analysis and interpretation, drafting of the article.

The original anonymized data are available on request from the cor- 

Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2

Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection